Scholarlink

Background <p>Health Canada, Canada’s national regulatory agency, conditionally approves new drugs and new indications for existing drugs (grants them a Notice of Compliance with conditions, NOC/c) and then requires confirmatory studies to validate efficacy and safety. Delays can occur between the expected time of submission of confirmatory studies and the actual time. Health Canada does not report on the status of ongoing confirmatory studies.</p> Objective <p>This study looks at whether delays exist, how often they occur, and how long they are. The additional therapeutic value of drugs was assessed to determine if delays might have had therapeutic implications.</p> Design <p>Cross-sectional.</p> <p>Participants</p> <p>Drugs receiving a conditional approval between September 1, 2012, and May 31, 2025, and had information about when submissions of the results of confirmatory studies were expected and when they were actually submitted.</p> <p>Interventions</p> <p>None.</p> <p>Main Measures</p> <p>Percent of drugs that had information about when submissions were expected. Delay between expected and actual submission of results. Additional therapeutic value of drugs. Whether orphan drug status, number of confirmatory studies, and anatomic/therapeutic/chemical status predicted the length of delay.</p> <p>Key Results</p> <p>Twenty-four (25%) of 96 drugs approved had information about when submissions were expected. Six drugs were excluded for a variety of reasons. Thirteen drugs had delays with a median of 636&#xa0;days (IQR 184, 1049) (1.74&#xa0;years). Three drugs had major new therapeutic value; 9 and 8 drugs had moderate and minor additional value, respectively. The multiple linear regression model was not significant, <i>F</i>(3,14) = 2.606, <i>p</i> = 0.0930.</p> Conclusions <p>Health Canada should publicly report on the criteria it uses to set dates of expected submission of confirmatory studies and consistently and publicly report those dates. It should annually make public the progress of studies and the reasons why they are delayed.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Delay in the Submission of the Results of Confirmatory Studies to Health Canada: A Cross-Sectional Study

  • 期刊论文

  • 发表日期：

    2025年11月11日

查看全文
  • Joel Lexchin

摘要

Background

Health Canada, Canada’s national regulatory agency, conditionally approves new drugs and new indications for existing drugs (grants them a Notice of Compliance with conditions, NOC/c) and then requires confirmatory studies to validate efficacy and safety. Delays can occur between the expected time of submission of confirmatory studies and the actual time. Health Canada does not report on the status of ongoing confirmatory studies.

Objective

This study looks at whether delays exist, how often they occur, and how long they are. The additional therapeutic value of drugs was assessed to determine if delays might have had therapeutic implications.

Design

Cross-sectional.

Participants

Drugs receiving a conditional approval between September 1, 2012, and May 31, 2025, and had information about when submissions of the results of confirmatory studies were expected and when they were actually submitted.

Interventions

None.

Main Measures

Percent of drugs that had information about when submissions were expected. Delay between expected and actual submission of results. Additional therapeutic value of drugs. Whether orphan drug status, number of confirmatory studies, and anatomic/therapeutic/chemical status predicted the length of delay.

Key Results

Twenty-four (25%) of 96 drugs approved had information about when submissions were expected. Six drugs were excluded for a variety of reasons. Thirteen drugs had delays with a median of 636 days (IQR 184, 1049) (1.74 years). Three drugs had major new therapeutic value; 9 and 8 drugs had moderate and minor additional value, respectively. The multiple linear regression model was not significant, F(3,14) = 2.606, p = 0.0930.

Conclusions

Health Canada should publicly report on the criteria it uses to set dates of expected submission of confirmatory studies and consistently and publicly report those dates. It should annually make public the progress of studies and the reasons why they are delayed.